Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.47 |
| ▸ | HRH2 | P25021 | 4/20 | 0.47 |
| ▸ | HRH1 | P35367 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2990304 | 0.91 | HRH3 (0.55) | HRH3HRH2HRH1CYP3A4CYP2C9 | |
| SCHEMBL2984514 | 0.85 | HRH3 (0.65) | HRH3HRH2HRH1NPC1RAB9A | |
| SCHEMBL2981461 | 0.82 | LTA4H (0.56) | HRH3HRH2HRH1TBK1LTA4H | |
| SCHEMBL2989450 | 0.82 | PRKCQ (0.49) | HRH3HRH2HRH1NPC1RAB9A | |
| SCHEMBL2975452 | 0.81 | HRH3 (0.55) | HRH3HRH2HRH1TBK1LTA4H | |
| SCHEMBL2981970 | 0.78 | HRH3 (0.64) | HRH3HRH2HRH1 | |
| SCHEMBL2984892 | 0.76 | HRH3 (0.64) | HRH3HRH2HRH1 | |
| SCHEMBL2975828 | 0.76 | SLC6A2 (0.58) | HRH3HRH1 | |
| SCHEMBL11091313 | 0.73 | MKNK1 (0.48) | HRH3HRH2HRH1NPC1RAB9A | |
| SCHEMBL2990306 | 0.73 | PRKCQ (0.57) | HRH3HRH2HRH1KDRTBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781591-B2 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC (US) | 2010-08-24 | — | — | US | disclosed |
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | CNKSR1, MAP3K1, MAP3K7 | HRH3 631/4885HRH2 936/4885HRH1 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.